Small Cap Losers: ORPH, CRIS, APTO
1:05 pm Monday, June 14th, 2021
Orphazyme A S ADR (NASDAQ: ORPH) slumped 52% to $10.15. Continued volatility; the stock pulls back after spiking yesterday and closing the session with gains of approx. +302%. Co, commenting on yesterday’s volatility, stated that it is not aware of any material change in its clinical programs, financial condition, or operational results that would explain the volume or volatility.
Curis, Inc. (NASDAQ: CRIS) stock fell 36.55% after the company announced updated data from its Phase 1/2 study of CA-4948 monotherapy in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes. Co has concluded that the 300mg BID dose is the optimal dose to take into Phase 2 studies; co observed several dose limiting toxicities in patients at the higher 400mg and 500mg dose levels, including Grade 3 rhabdomyolysis. Drops to its lowest levels since December.
Aptose Biosciences Inc (NASDAQ: APTO) slid 33.54% to $3.68 as the company presented on the current clinical status of luxeptinib, currently being developed for patients in relapsed or refractory acute myeloid leukemia and, separately, in patients with relapsed or refractory B cell malignancies. Co plans to escalate doses further in AML and MDS; in the B cell malignancies program, co is currently treating patients at 750mg BID and plans to continue further escalation to higher dose levels and for an extended duration to tackle an increasingly refractory presenting population.
